Merck Partners with Indian Manufacturers to Scale HIV Prevention in 129 Nations
Merck is licensing its experimental monthly HIV pill to seven manufacturers, including four major Indian firms, to expand access in developing countries. The royalty-free agreements aim to streamline production for 129 low- and middle-income nations following regulatory clearance.
Strategic Expansion of Investigational HIV Treatment
Pharmaceutical giant Merck, operating as MSD outside North America, has formalized non-exclusive voluntary licensing agreements to produce its experimental once-monthly oral HIV medication, Alimatravir. This proactive move involves four major Indian generic manufacturers—Aurobindo Pharma, Cipla, Emcure, and Viatris—alongside three additional firms located in sub-Saharan Africa. The royalty-free pacts bridge both public and private sectors, targeting 129 low- and middle-income countries where the majority of global HIV infections are documented.
Pre-Trial Strategy and Global Access
The timing of these agreements marks a shift in standard pharmaceutical rollout strategies. Aurobindo Pharma confirmed that signing these contracts before the completion of Phase 3 trial enrollment is an unprecedented step in the field of HIV prevention. This early-stage coordination prepares the infrastructure for immediate scale-up and high-volume manufacturing once the drug secures the necessary regulatory authorizations.
- Participating Indian Firms: Aurobindo Pharma, Cipla, Emcure, and Viatris.
- Regional Reach: 129 low- and middle-income countries.
- Financial Terms: Royalty-free licensing across seven global manufacturers.
- Product Profile: An oral, once-monthly investigational pill for HIV prevention.
Commitment to Scale and Standards
According to Umesh K, Associate President and Head of Global Access and Licensing at Aurobindo, the objective is to ensure that Alimatravir reaches eligible populations while maintaining international manufacturing standards. Gregg Szabo, Merck's Senior Vice President of Global HIV Marketing, noted that the collaboration represents a concerted effort to prepare supply chains for 129 nations ahead of potential approval. While clinical trials continue, these partnerships establish the groundwork for distributing the medication across territories with the highest disease burden.
Source: The Hindu — Business
